Christina Wu, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Exelixis
    Topic:
    hepatocellular cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    03/06/2024
  • Attribution:
    Other
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pfizer
    Topic:
    colorectal cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    08/16/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Merck
    Topic:
    colorectal cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    04/06/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Natera
    Topic:
    Signatera in colorectal cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    06/12/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    DoMore Diagnostics
    Topic:
    colon cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    12/21/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    GSK
    Topic:
    colon cancer
    Date added:
    09/25/2025
    Date updated:
    09/25/2025
    Relationship end date:
    02/12/2026
Return to Phoenix Precision Oncology Conference: Evidence to Practice